Properties |
Information |
PhytoCAT-ID |
PhytoCAT-245 |
Phytochemical name or plant extracts |
Lycopene |
PMID |
31404596 |
Literature evidence |
Aberrant activity of sirtuins (SIRTs) has strong implications in the metastatic and oncogenic progression of TNBC. |
IUPAC name |
(6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene |
Phytochemicals’ class or type of plant extracts |
Terpenoid |
Source of phytochemicals or plant Extracts |
Solanum lycopersicum |
|
Geographical availability |
Peru |
Plant parts |
NA |
Other cancers |
Breast cancer |
Target gene or protein |
BRCA1, BRCA2 |
Gene or Protein evidence |
Quantification by affinity perfusion chromatography of phosphorylated BRCAl and BRCA2 proteins from tumor cells after lycopene treatment. |
Target pathways |
In conclusion, the anticancer properties of lycopene may occur through inhibition of the NF-κB signaling pathway, beginning at the early stage of cytoplasmic IKK kinase activity, which then leads to reduced NF-κB-responsive gene regulation. Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC |
IC50 |
NA |
Potency |
We studied the effect of the potent dietary antioxidant lycopene on multiple points along the nuclear factor kappa B (NF-κB) signaling pathway in prostate and breast cancer cells. |
Cell line/ mice model |
MDA-MB-231, MCF-7, HT-29, T84 |
Additional information |
Bioactive compounds such as lycopene and lutein, derived from natural plant sources, have been shown to act at low substrate levels through the action of intrinsic cytokines and growth factors and their receptors within tissues, particularly those of the fibroblast growth factor and transforming growth factor beta families. |
PubChem ID |
446925 |
Additional PMIDs |
26779636 17640163 |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:316947-2 |
Safety |
NA |